<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39556760</PMID><DateCompleted><Year>2024</Year><Month>11</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>11</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1091-6490</ISSN><JournalIssue CitedMedium="Internet"><Volume>121</Volume><Issue>49</Issue><PubDate><Year>2024</Year><Month>Dec</Month><Day>03</Day></PubDate></JournalIssue><Title>Proceedings of the National Academy of Sciences of the United States of America</Title><ISOAbbreviation>Proc Natl Acad Sci U S A</ISOAbbreviation></Journal><ArticleTitle>Global trends in antibiotic consumption during 2016-2023 and future projections through 2030.</ArticleTitle><Pagination><StartPage>e2411919121</StartPage><MedlinePgn>e2411919121</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1073/pnas.2411919121</ELocationID><Abstract><AbstractText>Antibiotic resistance is a global public health threat. Many factors contribute to this issue, with human antibiotic consumption being significant among them. Analyzing trends and patterns in consumption can aid in developing policies to mitigate the burden of antimicrobial resistance and global disparities in access to antibiotics. Using pharmaceutical sales data licensed from IQVIA, we estimate national-level trends in antibiotic consumption in 67 countries during 2016-2023 and analyze the effects of economic growth and the COVID-19 pandemic. Finally, we estimate global human consumption and project growth through 2030 assuming current trends. We find that estimated antibiotic consumption in reported countries increased 16.3% from 29.5 to 34.3 billion defined daily doses (DDDs) from 2016 to 2023, reflecting a 10.6% increase in the consumption rate from 13.7 to 15.2 DDDs per 1,000 inhabitants per day. Increases were most pronounced in upper-middle- and lower-middle-income countries. While the COVID-19 pandemic significantly reduced consumption globally, this was most pronounced in high-income countries, and in these countries, reductions in antibiotic use in 2020 were sharper, and lasted longer, than in other countries. By 2030, we project that, without reductions in rapidly developing nations, such as investments to improve infrastructure, particularly water and sanitation, along with improved access to vaccination, global antibiotic consumption will increase by 52.3% from an estimated 49.3 billion in 2023 to 75.1 billion DDDs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Eili Y</ForeName><Initials>EY</Initials><Identifier Source="ORCID">0000-0002-1304-5289</Identifier><AffiliationInfo><Affiliation>One Health Trust, Washington, DC 20015.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Emergency Medicine, Johns Hopkins School of Medicine, Baltimore, MD 21287.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Impalli</LastName><ForeName>Isabella</ForeName><Initials>I</Initials><Identifier Source="ORCID">0009-0004-6596-4908</Identifier><AffiliationInfo><Affiliation>One Health Trust, Washington, DC 20015.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poleon</LastName><ForeName>Suprena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>One Health Trust, Washington, DC 20015.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denoel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0001-9863-6685</Identifier><AffiliationInfo><Affiliation>GSK, Vaccines R&amp;D, Rixensart 1330, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cipriano</LastName><ForeName>Mariateresa</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6644-7137</Identifier><AffiliationInfo><Affiliation>GSK, Vaccines R&amp;D, Siena 53100, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Boeckel</LastName><ForeName>Thomas P</ForeName><Initials>TP</Initials><AffiliationInfo><Affiliation>One Health Trust, Washington, DC 20015.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>One Health Institute, University of Zürich, Zürich 8057, Switzerland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spatial Epidemiology Lab, Université Libre de Bruxelles, Brussels B-1050, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pecetta</LastName><ForeName>Simone</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>GSK, Vaccines R&amp;D, Siena 53100, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bloom</LastName><ForeName>David E</ForeName><Initials>DE</Initials><AffiliationInfo><Affiliation>Harvard T. H. Chan School of Public Health, Boston, MA 02115.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nandi</LastName><ForeName>Arindam</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3967-2424</Identifier><AffiliationInfo><Affiliation>One Health Trust, Washington, DC 20015.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Population Council, New York, NY 10017.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>11</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Proc Natl Acad Sci U S A</MedlineTA><NlmUniqueID>7505876</NlmUniqueID><ISSNLinking>0027-8424</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="Y">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014943" MajorTopicYN="Y">Global Health</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004352" MajorTopicYN="N">Drug Resistance, Microbial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005544" MajorTopicYN="N">Forecasting</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">AMR</Keyword><Keyword MajorTopicYN="N">antibiotic resistance</Keyword><Keyword MajorTopicYN="N">antimicrobial resistance</Keyword><Keyword MajorTopicYN="N">global public health</Keyword></KeywordList><CoiStatement>Competing interests statement:P.D. and M.C. are employees of GSK group of companies. S. Pecetta was a GSK employee when the project started and he is currently an employee of Moderna Inc. D.E.B. has previously received research support or personal fees from GlaxoSmithKline plc, Merck, Pfizer, and Sanofi-Pasteur related to value-of-vaccination research, but not for this study. All other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>11</Month><Day>19</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>22</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>11</Month><Day>18</Day><Hour>15</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39556760</ArticleId><ArticleId IdType="doi">10.1073/pnas.2411919121</ArticleId></ArticleIdList></PubmedData></PubmedArticle>